

Adenosine Receptor A3 - Pipeline Review, H2 2020

<https://marketpublishers.com/r/A091F67F0FDBEN.html>

Date: October 2020

Pages: 89

Price: US\$ 3,500.00 (Single User License)

ID: A091F67F0FDBEN

Abstracts

Adenosine Receptor A3 - Pipeline Review, H2 2020

SUMMARY

Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Adenosine Receptor A3 - Pipeline Review, H2 2020, outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia. It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 1, 6, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Immunology, Gastrointestinal, Metabolic Disorders, Central Nervous System, Genito Urinary System And Sex Hormones, Male Health, Oncology, Ophthalmology, Infectious Disease, Musculoskeletal Disorders, Respiratory and Women's Health which include indications Non-Alcoholic Steatohepatitis (NASH), Diabetic Nephropathy, Glaucoma, Inflammation, Kidney Fibrosis, Rheumatoid Arthritis, Arthritis, Autoimmune Disorders, Chemotherapy Induced Pain, Chronic Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Colon

Cancer, Coronavirus Disease 2019 (COVID-19), Erectile Dysfunction, Female Sexual Dysfunction, Hepatocellular Carcinoma, Inflammatory Pain, Liver Cancer, Male Sexual Dysfunction, Melanoma, Neurodegenerative Diseases, Neuropathic Pain (Neuralgia), Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis and Ulcerative Colitis. Furthermore, this report also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)

The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects

The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Adenosine Receptor A3 (ADORA3) - Overview

Adenosine Receptor A3 (ADORA3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development

BioIntervene Inc

Can-Fite BioPharma Ltd

Future Medicine Co Ltd

Palo BioFarma SL

Adenosine Receptor A3 (ADORA3) - Drug Profiles

BIO-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-1888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-2698 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

namodenoson - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-1650 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-677 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piclidenoson - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ADORA3 for Chronic Obstructive Pulmonary Disease -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Autoimmune Disorders, Inflammation, Liver Cancer and Metabolic
Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize ADORA3 for Chronic Inflammation and Neurodegenerative

Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Adenosine Receptor A3 (ADORA3) - Dormant Products

Adenosine Receptor A3 (ADORA3) - Discontinued Products

Adenosine Receptor A3 (ADORA3) - Product Development Milestones

Featured News & Press Releases

Sep 30, 2020: Can-Fite selected to deliver late-breaking oral presentation on Namodenoson's treatment of NASH at American Association for the Study of Liver Diseases Conference

Aug 31, 2020: FDA clears Can-Fite to commence phase II COVID-19 study

Aug 25, 2020: Can-Fite receives notification of patent grant from European Patent Office for Namodenoson in the treatment of NASH

Jul 27, 2020: Can-Fite submits Investigational New Drug Application to U.S. FDA for COVID-19 phase II Study

Jul 20, 2020: Can-Fite completes development of an assay to identify clinically active cannabis derived compounds

Jul 15, 2020: Can-Fite completes phase II COVID-19 protocol based on FDA guidance, plans to file IND shortly

Jun 30, 2020: Can-Fite announces final data analysis from phase II NASH study: Highly significant and sustained reduction in liver fat volume throughout study period

Jun 09, 2020: Following Pre-IND guidance from FDA Can-Fite to Advance Piclidenoson into phase II COVID-19 trial in the U.S.

Jun 08, 2020: Can-Fite participating in BIO Digital International Convention and One-on-One partnering meetings on June 8-12, 2020

Jun 05, 2020: Can-Fite plans Phase III liver cancer trial of Namodenoson in Europe

May 21, 2020: Can-Fite receives notice of allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office

May 18, 2020: Can-Fite reports additional findings from successful phase II NASH Study: 25 mg Dose of namodenoson significantly reduced liver fat and fibrosis

May 15, 2020: Can-Fite announces pre-IND submission to U.S. FDA for Piclidenoson in the treatment of covid-19 infected patients with moderate-to-severe symptoms

Apr 14, 2020: Can Fite to conduct investor call to review positive phase II NASH data

Apr 13, 2020: Can Fite received approval for covid-19 clinical trial in Israel, patient enrollment and dosing to commence immediately

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by BioIntervene Inc, H2 2020
Pipeline by Can-Fite BioPharma Ltd, H2 2020
Pipeline by Future Medicine Co Ltd, H2 2020
Pipeline by Palo BioFarma SL, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

I would like to order

Product name: Adenosine Receptor A3 - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/A091F67F0FDBEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A091F67F0FDBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970